OptimizeRx Corp(OPRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,106 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OPRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for OptimizeRx Corp (OPRX), a Industrials sector company. 13F Pro's AI-powered ranking engine scores OPRX at 57.4/100 on a 32-signal composite quality model, placing it at rank #1,106 of 2,962 stocks — the top half of the AI-ranked universe. OPRX scores in the top quartile across earnings quality (86.6), revenue growth (79.7). Areas of concern include institutional flow (3.7) and revenue scale (15.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), OptimizeRx Corp reports quarterly revenue of $20.5M, net income of $-703.0K, free cash flow of $8.6M. Top institutional holders of OPRX by reported 13-F value include Whetstone Capital Advisors, ROYCE & ASSOCIATES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. OPRX trades on the Nasdaq exchange and files with the SEC under CIK 1448431. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OptimizeRx Corp directly from SEC EDGAR. OptimizeRx Corp's 13F Pro composite quality score has ranged between 24 and 59 since 2021, currently 57.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$20.5M
Net Income
Q2 2026
$-703.0K
Free Cash Flow
Q2 2026
$8.6M
ROIC
Q2 2026
-0.2%
D/E Ratio
Q2 2026
0.16
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+18.8% YoYNet Income
+125.5% YoYOperating Income
+185.3% YoYEPS (Diluted)
+124.5% YoYTotal Assets
+3.4% YoYTotal Debt
-15.8% YoYOp. Cash Flow
+282.8% YoYFree Cash Flow
+290.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.4M +18.8% | $92.1M +28.8% | $71.5M +14.5% | $62.5M +1.9% | $61.3M +41.5% | $43.3M |
| Net Income | $5.1M +125.5% | $-20.1M -14.5% | $-17.6M -53.6% | $-11.4M -3125.4% | $378.1K +117.1% | $-2.2M |
| Operating Income | $11.7M +185.3% | $-13.7M +48.1% | $-26.4M -114.8% | $-12.3M -3503.7% | $361.1K +116.9% | $-2.1M |
| EPS (Diluted) | $0.27 +124.5% | $-1.10 -6.8% | $-1.03 -60.9% | $-0.64 -3300.0% | $0.02 +113.3% | $-0.15 |
| Total Assets | $176.9M +3.4% | $171.2M -6.7% | $183.4M +36.2% | $134.7M -4.5% | $141.0M +133.7% | $60.3M |
| Total Debt | $30.5M -15.8% | $36.3M -9.9% | $40.3M | — | — | — |
| Operating Cash Flow | $18.7M +282.8% | $4.9M +167.5% | $-7.2M -168.0% | $10.7M +1367.4% | $726.0K +111.5% | $-6.3M |
| Free Cash Flow | $18.7M +290.6% | $4.8M +165.2% | $-7.3M -169.3% | $10.6M +1589.8% | $625.7K +109.8% | $-6.4M |
Get alerted when OPRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for OptimizeRx Corp including:
Top Institutional Holders of OPRX
Whetstone Capital Advisors, LLC
$8.6M1,508,303 shROYCE & ASSOCIATES LP
$6.2M1,089,398 shVANGUARD CAPITAL MANAGEMENT LLC
$4.0M699,604 shKENNEDY CAPITAL MANAGEMENT LLC
$3.7M644,150 shRICE HALL JAMES & ASSOCIATES, LLC
$3.6M633,842 shBLAIR WILLIAM & CO/IL
$3.5M607,925 shAQR CAPITAL MANAGEMENT LLC
$3.3M583,956 shDIMENSIONAL FUND ADVISORS LP
$2.7M477,687 shBlackRock, Inc.
$2.5M445,382 shParkman Healthcare Partners LLC
$2.0M350,347 sh
| Fund | Value | Shares |
|---|---|---|
| Whetstone Capital Advisors, LLC | $8.6M | 1,508,303 |
| ROYCE & ASSOCIATES LP | $6.2M | 1,089,398 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.0M | 699,604 |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.7M | 644,150 |
| RICE HALL JAMES & ASSOCIATES, LLC | $3.6M | 633,842 |
| BLAIR WILLIAM & CO/IL | $3.5M | 607,925 |
| AQR CAPITAL MANAGEMENT LLC | $3.3M | 583,956 |
| DIMENSIONAL FUND ADVISORS LP | $2.7M | 477,687 |
| BlackRock, Inc. | $2.5M | 445,382 |
| Parkman Healthcare Partners LLC | $2.0M | 350,347 |
Companies Similar to OPRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Fiverr International Ltd.
ACME UNITED CORP
Phreesia, Inc.
Rimini Street, Inc.
RADWARE LTD
RCM TECHNOLOGIES, INC.
Energy Recovery, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Industrials Companies
View all Industrials →Put OPRX on your watchlist
Track score changes the day OptimizeRx Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OPRX a good stock to buy?
13F Pro's AI-powered analysis of OptimizeRx Corp (OPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OPRX are available on the OPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OPRX is classified as a small company.
Which hedge funds own OPRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OptimizeRx Corp's investment landscape.